JP4670040B2 - コラーゲン産生能向上剤 - Google Patents
コラーゲン産生能向上剤 Download PDFInfo
- Publication number
- JP4670040B2 JP4670040B2 JP2004343641A JP2004343641A JP4670040B2 JP 4670040 B2 JP4670040 B2 JP 4670040B2 JP 2004343641 A JP2004343641 A JP 2004343641A JP 2004343641 A JP2004343641 A JP 2004343641A JP 4670040 B2 JP4670040 B2 JP 4670040B2
- Authority
- JP
- Japan
- Prior art keywords
- collagen
- amount
- compound
- glutathione
- fibroblasts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000037319 collagen production Effects 0.000 title description 35
- 239000002537 cosmetic Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 25
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 9
- 230000009759 skin aging Effects 0.000 claims description 9
- 230000003020 moisturizing effect Effects 0.000 claims description 6
- 230000037393 skin firmness Effects 0.000 claims description 3
- NKRBAUXTIWONOV-UHFFFAOYSA-N 1'-Acetoxyeugenol acetate Natural products COC1=CC(C(OC(C)=O)C=C)=CC=C1OC(C)=O NKRBAUXTIWONOV-UHFFFAOYSA-N 0.000 claims 1
- JAMQIUWGGBSIKZ-ZDUSSCGKSA-N 1'-acetoxychavicol acetate Chemical compound CC(=O)O[C@@H](C=C)C1=CC=C(OC(C)=O)C=C1 JAMQIUWGGBSIKZ-ZDUSSCGKSA-N 0.000 claims 1
- JAMQIUWGGBSIKZ-UHFFFAOYSA-N rac-galangal acetate Natural products CC(=O)OC(C=C)C1=CC=C(OC(C)=O)C=C1 JAMQIUWGGBSIKZ-UHFFFAOYSA-N 0.000 claims 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 90
- 150000001875 compounds Chemical class 0.000 description 69
- 108010024636 Glutathione Proteins 0.000 description 45
- 229960003180 glutathione Drugs 0.000 description 45
- 102000008186 Collagen Human genes 0.000 description 35
- 108010035532 Collagen Proteins 0.000 description 35
- 229920001436 collagen Polymers 0.000 description 35
- 238000000034 method Methods 0.000 description 33
- 210000002950 fibroblast Anatomy 0.000 description 31
- 238000012216 screening Methods 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 21
- 230000007423 decrease Effects 0.000 description 21
- 230000003834 intracellular effect Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 14
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 229960003330 pentetic acid Drugs 0.000 description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 210000001626 skin fibroblast Anatomy 0.000 description 10
- MMTOZJBMQSASCE-UHFFFAOYSA-N 1,4-dipyridin-2-yl-2,3-bis(pyridin-2-ylmethyl)butane-2,3-diamine Chemical compound C=1C=CC=NC=1CC(C(N)(CC=1N=CC=CC=1)CC=1N=CC=CC=1)(N)CC1=CC=CC=N1 MMTOZJBMQSASCE-UHFFFAOYSA-N 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 102000012422 Collagen Type I Human genes 0.000 description 6
- 108010022452 Collagen Type I Proteins 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000004024 hepatic stellate cell Anatomy 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 2
- 230000036558 skin tension Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HJFCVJKLGPYQDB-UHFFFAOYSA-N 5-(4-aminophenyl)cyclohexa-2,4-diene-1,1,2-triamine Chemical compound C1C(N)(N)C(N)=CC=C1C1=CC=C(N)C=C1 HJFCVJKLGPYQDB-UHFFFAOYSA-N 0.000 description 1
- YCPXWRQRBFJBPZ-UHFFFAOYSA-N 5-sulfosalicylic acid Chemical compound OC(=O)C1=CC(S(O)(=O)=O)=CC=C1O YCPXWRQRBFJBPZ-UHFFFAOYSA-N 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 239000011665 D-biotin Substances 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010036164 Glutathione synthase Proteins 0.000 description 1
- 102100034294 Glutathione synthetase Human genes 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229930190887 Leptomycin Natural products 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 230000007691 collagen metabolic process Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- YACHGFWEQXFSBS-RJXCBBHPSA-N leptomycin Chemical compound OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)\C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-RJXCBBHPSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- JAOSYYPULNBONK-UHFFFAOYSA-N n'-(pyridin-2-ylmethyl)ethane-1,2-diamine Chemical compound NCCNCC1=CC=CC=N1 JAOSYYPULNBONK-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229940054441 o-phthalaldehyde Drugs 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 102220288073 rs151218932 Human genes 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明のコラーゲン産生能向上剤は、線維芽細胞内グルタチオン量を減少させる化合物を有効成分とする。
本発明の化粧用組成物は、上記コラーゲン産生能向上剤を含有することを特徴とする。
本発明のスクリーニング方法は、本発明のコラーゲン産生能向上剤の有効成分となる化合物、言い換えると、コラーゲン産生能向上化合物を効率良くスクリーニングする方法である。
細胞内グルタチオン量を指標として線維芽細胞内グルタチオン量を減少させる化合物を選別することを特徴とするコラーゲン産生能向上化合物のスクリーニング方法が挙げられる。
(1)細胞又は細胞培養物に被験化合物を接触させ、細胞内グルタチオン量を測定する工程、(2)(1)における測定値を被験化合物と接触させない対照(コントロール)における測定値と比較する工程、(3)(2)の結果に基づいて、線維芽細胞内グルタチオン量を減少させる化合物を選別する工程を有するコラーゲン産生能向上化合物のスクリーニング方法も挙げられる。
以下のような実験を行なって、線維芽細胞内グルタチオン量を減少させる化合物のスクリーニングを行なった。
上記のスクリーニングによって得られた化合物のコラーゲン産生能向上作用を調べるために、以下の実験を行なった。
ヒト正常皮膚由来線維芽細胞(CCD-1059SK、大日本製薬株式会社)を、10%FBS(fetal bovine serum)を含むEMEM培地で3〜6回継代培養した。次いで、細胞数が1×106個になるようにカルチャースライド(Culture slide:Falcon社製)に調製し、10%FBSを含むEMEM培地で24時間培養して、細胞をスライドに固定させ、更に、細胞周期を合わせるためにEMEM培地のみで24時間培養した。その後、10%FBSを含むEMEM培地に交換し、同時に被験化合物を添加して24時間培養して、以下に示す各サンプル群を調製した。また、コントロールとして被験化合物を添加しない群、ポジティブコントロールとして、ビタミンC(VC)添加群を調製した。
1)コントロール群
2)DTPA 10μM添加群
3)DTPA 50μM添加群
4)ACA 1μM添加群
5)TPEN 1μM添加群
6)VC 114μM添加群(ポジティブコントロール)
(1)で調製した1)〜6)のサンプル群について、次の手順により、コラーゲンの産生量を免疫組織化学的に解析した。
Claims (3)
- 1’−アセトキシチャビコールアセテート(1’-acetoxychavicol acetate)を含有する、皮膚の老化防止及び/又は改善用の化粧用組成物。
- 1’−アセトキシチャビコールアセテートを含有する、皮膚のハリ及び艶維持改善用又は皮膚の保湿機能維持改善用の請求項1に記載の化粧用組成物。
- 請求項1又は2に記載の化粧用組成物を用いて製造される、化粧品又は化粧料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004343641A JP4670040B2 (ja) | 2004-11-29 | 2004-11-29 | コラーゲン産生能向上剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004343641A JP4670040B2 (ja) | 2004-11-29 | 2004-11-29 | コラーゲン産生能向上剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006151860A JP2006151860A (ja) | 2006-06-15 |
JP4670040B2 true JP4670040B2 (ja) | 2011-04-13 |
Family
ID=36630576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004343641A Active JP4670040B2 (ja) | 2004-11-29 | 2004-11-29 | コラーゲン産生能向上剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4670040B2 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5610681B2 (ja) * | 2008-09-19 | 2014-10-22 | 株式会社ノエビア | 中性脂肪蓄積抑制剤 |
WO2010123102A1 (ja) * | 2009-04-24 | 2010-10-28 | Yuasa Isao | コラーゲン産生促進剤、光老化防止剤、保湿機能改善剤および皮膚用剤組成物 |
JP5737889B2 (ja) * | 2010-09-09 | 2015-06-17 | 公立大学法人大阪市立大学 | 抗肥満剤 |
JP2013193994A (ja) * | 2012-03-21 | 2013-09-30 | Osaka City Univ | 皮膚再生促進剤 |
JP7265015B2 (ja) * | 2019-08-09 | 2023-04-25 | 株式会社 資生堂 | 神経活性化を指標とした線維芽細胞i型コラーゲン産生促進剤のスクリーニング方法、及び神経活性化剤を含む線維芽細胞i型コラーゲン産生促進剤 |
CN116251100B (zh) * | 2023-04-04 | 2023-09-19 | 北京大学 | Tpen在制备抗皮肤衰老或抗皮炎的组合物产品中的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003009807A2 (en) * | 2001-07-23 | 2003-02-06 | Galileo Laboratories, Inc. | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
-
2004
- 2004-11-29 JP JP2004343641A patent/JP4670040B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2006151860A (ja) | 2006-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101332157B (zh) | 半胱氨酸衍生物 | |
US20090130139A1 (en) | Cosmetic active ingredient composed of arginine ferrulate and a microalgae extract and its uses | |
WO2018081779A1 (en) | Skin enhancing compositions and methods | |
JP4670040B2 (ja) | コラーゲン産生能向上剤 | |
JP2022513171A (ja) | 皮膚症状を改善するためのポリペプチドおよび方法 | |
KR20120116900A (ko) | 백모증의 처리를 위한, 멜라닌 세포 내 글루타티온 수치를 증가시킬 수 있는 화합물의 용도 | |
TW201729794A (zh) | 用於調整膚質之化妝品組成物及其用途 | |
US10105313B2 (en) | Uses of rose pigment compounds | |
JP2015534644A (ja) | 有益剤及びこれを含む組成物の特定又は評価方法 | |
KR101629299B1 (ko) | 식물성 버터 또는 지용성 비타민 c 유도체가 표면처리된 코팅분체 및 그 코팅분체들을 포함한 화장료 조성물 | |
US11137387B2 (en) | Method of identifying or evaluating synergistic combinations of actives and compositions containing the same | |
JP2010081913A (ja) | シミ改善効果及び/または美白効果を発揮する有効成分のスクリーニング方法 | |
KR20230164937A (ko) | 신규한 미백 펩타이드 및 이를 함유하는 화장료 조성물 | |
US20230201097A1 (en) | Composition for inhibiting hair graying, and use thereof | |
JP5207227B2 (ja) | コラーゲン産生促進剤 | |
US20160136078A1 (en) | Method for Stabilizing Ascorbic Acid Derivatives and the Application Thereof | |
EP1810716A1 (de) | Verfahren zur Bräunung der Haut | |
US20180078483A1 (en) | Novel uses of the peptide of sequence his-d-trp-ala-trp-d-phe-lys-nh2 for reducing or delaying the appearance of cell senescence and signs of skin aging | |
CN115227600B (zh) | 一种具有抗氧化美白的组合物及其制备方法和应用 | |
US20070065377A1 (en) | Composition for promoting synthesis of collagen, and composition for external preparation for skin comprising the same | |
KR20210093061A (ko) | 노화세포 회춘용 조성물 및 노화세포 회춘방법 | |
KR20230107926A (ko) | 펩타이드 혼합물을 함유하는 화장료 조성물 | |
DE102004048576A1 (de) | Methode zur Bräunung der Haut | |
WO2002060404A1 (en) | Composition of miconazole for external application and skin-whitening | |
KR20240032203A (ko) | 미백용 복합 펩타이드 및 이를 함유하는 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070810 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100811 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101006 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20101008 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101207 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20101224 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101224 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20101224 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4670040 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140128 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |